Catalent Biologics announces agreement with Moderna Therapeutics

Published: 14-Oct-2016
Research & Development Pharmaceutical

Companies to develop personalised cancer vaccines


Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has entered into an agreement with Moderna Therapeutics to support near-term clinical Good Manufacturing Practice (GMP) messenger RNA (mRNA) manufacturing efforts for Phase I/II clinical studies of the company’s mRNA personalised cancer vaccines.

Moderna is a clinical stage biotechnology company pioneering mRNA Therapeutics to create a new generation of transformative medicines for patients. Moderna, in collaboration with Merck, is advancing mRNA-based personalised cancer vaccines for patients across a spectrum of cancers. A clinical study of the personalised cancer vaccine is anticipated to begin in 2017.

Under the terms of the agreement, in place through 2018, Moderna will leverage Catalent’s manufacturing expertise and capabilities at its state-of-the-art facility in Madison, Wisconsin, USA, to support cGMP manufacturing of its mRNA personalised cancer vaccine clinical studies while the company builds out and transitions to its recently announced GMP mRNA clinical manufacturing facility in Norwood, Massachusetts, USA.

'We are extremely pleased to be selected to support Moderna’s Phase I/II clinical GMP manufacturing needs for its personalised cancer vaccines. Catalent’s Madison facility was designed and constructed to offer maximum flexibility and efficiency. At the facility, we will be able to offer Moderna a separate dedicated production capability and a highly flexible, fast turnaround operation to support initial study of its novel mRNA-based personalized cancer vaccines,' commented Brian Riley, General Manager of Catalent’s Madison facility.

Completed in June 2013, Catalent’s Madison facility was designed for both flexible cGMP and non-GMP production. The site features extensive single-use technologies and unidirectional flow to maximise efficiency and safety.

  • Companies:
  • Catalent
See more

You may also like

Research & Development

CPHI Barcelona Snapshot: Catalent

Read more
Influenced by the rising desire of biotechs to develop novel treatments, drug modalities entering the market are changing

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  4. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  5. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

CPHI Barcelona Snapshot: Catalent

Influenced by the rising desire of biotechs to develop novel treatments, drug modalities entering the market are changing
Manufacturing

Catalent adds cryogenic capabilities to support gene development

The facility in Shiga will include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials
Research & Development

Catalent and Grünenthal announce manufacturing collaboration

In this phase, Catalent supported Grünenthal with the development of a bioavailability enhanced formulation
Manufacturing

Catalent expands platform process for viral vectors

Processes can now benefit through increased consistency and efficiency, potentially reducing the time
Manufacturing

Exelixis and Catalent enter into new license agreement

New priority discovery programs focused on three oncology targets with potential to develop antibody-drug conjugates (ADCs) for a variety of solid tumor indications
Manufacturing

Why outsourcing makes sense for orphan and rare diseases

There are as many as 8000 rare diseases, affecting 400 million people worldwide, for which there are no effective drugs available.<sup>1</sup> With patient numbers being so low for each rare disease, it is often difficult for a pharmaceutical company to achieve a return on its investment on a drug development programme or treatment without additional incentives.
Manufacturing

Catalent expands clinical supply capabilities in Shanghai

A 30,000 sqft expansion will roughly double the site’s clinical storage capacity, while facilitating the installation of additional frozen storage
Subscribe now